MA46752A - Traitement de maladies du snc au moyen de stimulateurs de gcs - Google Patents

Traitement de maladies du snc au moyen de stimulateurs de gcs

Info

Publication number
MA46752A
MA46752A MA046752A MA46752A MA46752A MA 46752 A MA46752 A MA 46752A MA 046752 A MA046752 A MA 046752A MA 46752 A MA46752 A MA 46752A MA 46752 A MA46752 A MA 46752A
Authority
MA
Morocco
Prior art keywords
gcs
stimulators
treatment
cns diseases
cns
Prior art date
Application number
MA046752A
Other languages
English (en)
Inventor
Peter Germano
Rajesh R Iyengar
Joon Jung
Thomas Wai-Ho Lee
Nicholas Robert Perl
Maria D Ribadeneira
Kim Tang
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MA46752A publication Critical patent/MA46752A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046752A 2016-11-08 2017-11-07 Traitement de maladies du snc au moyen de stimulateurs de gcs MA46752A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08

Publications (1)

Publication Number Publication Date
MA46752A true MA46752A (fr) 2019-09-18

Family

ID=60452769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046752A MA46752A (fr) 2016-11-08 2017-11-07 Traitement de maladies du snc au moyen de stimulateurs de gcs

Country Status (19)

Country Link
US (4) US11690828B2 (fr)
EP (1) EP3538096B1 (fr)
JP (2) JP7150740B2 (fr)
KR (1) KR102475124B1 (fr)
CN (1) CN110267658B (fr)
AU (2) AU2017359018C1 (fr)
BR (1) BR112019009449A2 (fr)
CA (1) CA3042548A1 (fr)
CL (1) CL2019001256A1 (fr)
EA (1) EA201991147A1 (fr)
ES (1) ES2972711T3 (fr)
IL (1) IL266275B2 (fr)
MA (1) MA46752A (fr)
MX (2) MX2019005342A (fr)
NZ (1) NZ753434A (fr)
PH (1) PH12019501016A1 (fr)
SG (1) SG10202104865UA (fr)
TW (1) TWI812601B (fr)
WO (1) WO2018089328A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3059583T3 (en) * 2016-11-08 2026-03-23 Tisento Therapeutics Inc Sgc stimulators
US11389449B2 (en) 2017-09-14 2022-07-19 Cyclerion Therapeutics, Inc. Treatment of metabolic syndrome with an sGC stimulator
US12220414B2 (en) 2018-07-11 2025-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochondrial disorders
US20220087970A1 (en) * 2019-01-18 2022-03-24 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
US20230012071A1 (en) * 2019-12-05 2023-01-12 Zydus Lifesciences Limited Modified release pharmaceutical compositions of riociguat
KR102398219B1 (ko) 2020-02-07 2022-05-17 주식회사 뉴로벤티 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
WO2023130028A1 (fr) * 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Formulations orales de levosimendan pour le traitement de l'hypertension pulmonaire avec insuffisance cardiaque à fraction d'éjection préservée
KR20250160137A (ko) * 2023-02-03 2025-11-11 알.피.쉐러 테크놀러지즈 엘엘씨 삼투압 약학적 캡슐

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
DE3660408D1 (en) 1985-02-27 1988-08-25 Oerlikon Buehrle Ag Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
ES2251200T3 (es) 1998-07-08 2006-04-16 Sanofi-Aventis Deutschland Gmbh N-arilamidas del acido sulfonilaminocarboxilico sustituidas con azufre, su uso y preparaciones farmaceuticas que las comprenden.
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DK1140012T3 (da) 1998-12-17 2004-07-12 Alza Corp Omdannelse af væskefyldte gelatinekapsler til systemer til kontrolleret frigivelsessystemer ved flere coatinger
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2534371A1 (fr) 2003-08-04 2005-02-10 Pfizer Products Inc. Formes posologiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle et d'inhibiteurs de la hmg-coa-reductase
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
CN101939053A (zh) 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
EP2244575B1 (fr) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Antagonistes du récepteur de l'angiotensine ii
JP5501369B2 (ja) 2008-11-25 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
EP2401265B1 (fr) 2009-02-26 2016-09-14 Merck Sharp & Dohme Corp. Derives d'acide 1-pyri(mid)in-2-yl-pyrazole-4-carboxylique utiles dans la therapie ou la prophylaxie de maladies cardiovasculaires
EP2549875B1 (fr) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Activateurs de guanylate cyclase solubles
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MX2018007152A (es) * 2015-12-14 2018-08-15 Ironwood Pharmaceuticals Inc Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
WO2017108441A1 (fr) 2015-12-22 2017-06-29 Universiteit Maastricht Traitement de la déficience cognitive à l'aide d'un stimulateur de la sgc
WO2017121700A1 (fr) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Dérivés de 1h-pyrazolo[3,4-b]pyridine 1,3-disubstitués et leur utilisation en tant que stimulateurs de la guanylacte cyclase soluble
KR102568384B1 (ko) * 2016-09-02 2023-08-22 사이클리온 테라퓨틱스, 인크. 융합된 비시클릭 sGC 자극제

Also Published As

Publication number Publication date
JP2022160605A (ja) 2022-10-19
WO2018089328A1 (fr) 2018-05-17
EA201991147A1 (ru) 2019-11-29
AU2017359018B2 (en) 2023-08-31
EP3538096C0 (fr) 2024-02-28
AU2023270267A1 (en) 2023-12-07
US11690828B2 (en) 2023-07-04
JP2019534327A (ja) 2019-11-28
SG10202104865UA (en) 2021-06-29
IL266275A (en) 2019-06-30
IL266275B2 (en) 2023-12-01
TW201822765A (zh) 2018-07-01
WO2018089328A8 (fr) 2019-03-28
NZ753434A (en) 2025-10-31
EP3538096A1 (fr) 2019-09-18
CN110267658A (zh) 2019-09-20
IL266275B1 (en) 2023-08-01
PH12019501016A1 (en) 2019-09-09
CA3042548A1 (fr) 2018-05-17
US20250108040A1 (en) 2025-04-03
MX2019005342A (es) 2019-10-02
CN110267658B (zh) 2024-02-02
KR102475124B1 (ko) 2022-12-08
US20230381153A1 (en) 2023-11-30
AU2017359018C1 (en) 2023-12-21
JP7150740B2 (ja) 2022-10-11
BR112019009449A2 (pt) 2019-07-30
KR20190094167A (ko) 2019-08-12
CL2019001256A1 (es) 2019-10-04
US20190343813A1 (en) 2019-11-14
US20260000653A1 (en) 2026-01-01
AU2017359018A1 (en) 2019-05-30
EP3538096B1 (fr) 2024-02-28
ES2972711T3 (es) 2024-06-14
MX2022010852A (es) 2022-09-27
TWI812601B (zh) 2023-08-21

Similar Documents

Publication Publication Date Title
MA46752A (fr) Traitement de maladies du snc au moyen de stimulateurs de gcs
EP3548039A4 (fr) Méthodes de traitement de maladies associées au stress mitochondrial
MA47095A (fr) Traitement du palais mou
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3720553C0 (fr) Dispositif de photobiomodulation destiné au traitement d'une maladie rétinienne
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3875139C0 (fr) Traitement des maladies veineuses
EP3454945A4 (fr) Inhibiteurs de ash1l et méthodes de traitement au moyen de ceux-ci
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
FR25C1031I1 (fr) Traitement de maladies cholestatiques intrahepatiques
EP3448263A4 (fr) Traitement électrothérapeutique
EP2975055A4 (fr) Anticorps anti-c5 et méthode de prévention et de traitement de maladies liées au complément
EP3390666A4 (fr) Compositions et méthodes de traitement de maladies rénales
EP3273955A4 (fr) Traitement de maladies respiratoires
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
EP3373962A4 (fr) Compositions et méthodes de traitement de maladies auto-immunes et de cancers
EP3294274A4 (fr) Traitement de maladies du snc avec des cellules inductibles encapsulées de plexus choroïdes
MA42930A (fr) Traitement de maladies neurodégénératives
EP3364974A4 (fr) Modulateurs de maladies impliquant des télomères
DK3104852T3 (da) Sammensætninger og fremgangsmåde til behandling af aldring og aldersbetingede sygdomme og symptomer